Note: This study found no significant biological effects under its experimental conditions. We include all studies for scientific completeness.
Cancer & Tumors1,874 citations
Lai J, Zhang Y, Liu X, Zhang J, Ruan G, Chaugai S, Chen C, Wang DW
No Effects Found
Authors not listed · 2016
Genetic analysis of 1,122 brain tumors reveals distinct molecular subtypes that could improve treatment and patient outcomes.
Plain English Summary
Summary written for general audiences
This study analyzed genetic profiles from over 1,100 brain tumor samples to better understand diffuse gliomas (a type of brain cancer). Researchers found specific genetic mutations that help classify these tumors and predict patient outcomes. The findings may improve treatment approaches by identifying distinct molecular subtypes of brain tumors.
Cite This Study
Unknown (2016). Lai J, Zhang Y, Liu X, Zhang J, Ruan G, Chaugai S, Chen C, Wang DW.
Show BibTeX
@article{lai_j_zhang_y_liu_x_zhang_j_ruan_g_chaugai_s_chen_c_wang_dw_ce4454,
author = {Unknown},
title = {Lai J, Zhang Y, Liu X, Zhang J, Ruan G, Chaugai S, Chen C, Wang DW},
year = {2016},
doi = {10.1016/j.cell.2015.12.028},
}Quick Questions About This Study
The study identified key mutations including IDH gene changes and 1p/19q chromosomal deletions that help classify different glioma subtypes. ATRX mutations were associated with longer telomeres, while specific DNA methylation patterns distinguished clinically relevant tumor groups.
Researchers analyzed 1,122 diffuse grade II-III-IV glioma samples from The Cancer Genome Atlas, making this one of the largest comprehensive genomic studies of brain tumors to identify molecular classification systems.
Yes, the study found that DNA methylation profiles could identify clinically relevant molecular subsets. One IDH mutant glioma subtype showed DNA demethylation and poor outcomes, while another group had more favorable survival rates.
A group of IDH wild-type diffuse gliomas showed molecular similarity to pilocytic astrocytoma and had relatively favorable survival compared to other glioma types, suggesting they represent a distinct disease category.
Whole-genome sequencing revealed that ATRX mutations, but not TERT promoter mutations, are associated with increased telomere length in gliomas. This finding helps explain different molecular mechanisms driving these brain tumors.